Zenas BioPharma (NASDAQ:ZBIO) CEO Leon Moulder, Jr. Buys 25,000 Shares of Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. purchased 25,000 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The shares were bought at an average price of $18.02 per share, with a total value of $450,500.00. Following the purchase, the chief executive officer owned 1,751,039 shares in the company, valued at $31,553,722.78. This represents a 1.45% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Zenas BioPharma Stock Performance

ZBIO opened at $17.55 on Thursday. The stock has a 50-day moving average of $22.48 and a 200-day moving average of $27.14. Zenas BioPharma, Inc. has a 52-week low of $8.51 and a 52-week high of $44.60. The company has a market cap of $1.01 billion, a PE ratio of -2.25 and a beta of -0.54. The company has a debt-to-equity ratio of 0.32, a quick ratio of 5.61 and a current ratio of 5.61.

Zenas BioPharma (NASDAQ:ZBIO) last released its earnings results on Monday, April 13th. The company reported ($1.10) earnings per share (EPS) for the quarter. As a group, equities research analysts forecast that Zenas BioPharma, Inc. will post -4.97 earnings per share for the current fiscal year.

Institutional Trading of Zenas BioPharma

A number of hedge funds have recently modified their holdings of ZBIO. Geode Capital Management LLC lifted its position in shares of Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after acquiring an additional 16,461 shares during the period. Rhumbline Advisers lifted its position in shares of Zenas BioPharma by 71.3% in the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock worth $191,000 after acquiring an additional 8,207 shares during the period. Sei Investments Co. bought a new stake in shares of Zenas BioPharma in the 2nd quarter worth approximately $118,000. Bank of America Corp DE lifted its position in shares of Zenas BioPharma by 32.3% in the 2nd quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock worth $136,000 after acquiring an additional 3,412 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Zenas BioPharma by 17.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock worth $25,813,000 after acquiring an additional 170,546 shares during the period.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Wall Street Zen lowered Zenas BioPharma from a “hold” rating to a “strong sell” rating in a report on Saturday, March 21st. HC Wainwright reaffirmed a “buy” rating and issued a $44.00 target price on shares of Zenas BioPharma in a report on Tuesday, March 17th. Guggenheim raised their target price on Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday, March 16th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $48.00 target price on shares of Zenas BioPharma in a report on Tuesday, January 6th. Finally, Zacks Research lowered Zenas BioPharma from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 17th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $44.14.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.